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models.	However,	 translation	of	senolytic	 therapies	 to	human	disease	 is	hampered	
by	their	suboptimal	specificity	for	senescent	cells	and	important	toxicities	that	nar-





(Nav-Gal),	 that	 can	be	preferentially	activated	by	SA-β-gal activity in a wide range 
of cell types. Nav-Gal selectively induces senescent cell apoptosis and has a higher 
senolytic	 index	than	Navitoclax	 (through	reduced	activation	 in	nonsenescent	cells).	
Nav-Gal	enhances	the	cytotoxicity	of	standard	senescence-inducing	chemotherapy	
(cisplatin)	in	human	A549	lung	cancer	cells.	Concomitant	treatment	with	cisplatin	and	
Nav-Gal in vivo results in the eradication of senescent lung cancer cells and signifi-
cantly	reduces	tumour	growth.	Importantly,	galacto-conjugation	reduces	Navitoclax-
induced	platelet	apoptosis	in	human	and	murine	blood	samples	treated	ex	vivo,	and	
thrombocytopenia at therapeutically effective concentrations in murine lung cancer 
models.	Taken	together,	we	provide	a	potentially	versatile	strategy	for	generating	ef-
fective	senolytic	prodrugs	with	reduced	toxicities.





secretory	 phenotype,	 termed	 the	 senescence-associated	 secretory	
phenotype	(SASP)	 (Gorgoulis	et	al.,	2019).	Physiological	roles	of	cel-
lular senescence include prevention of the propagation of damaged or 
dysfunctional cells and promotion of tissue repair; these processes are 
facilitated by immune system cells driving the clearance of senescent 
cells	(Muñoz-Espín	&	Serrano,	2014).	Senescence	plays	an	active	role	
in	 tumour	 suppression,	 reprogramming,	 tissue	 regeneration,	 wound	
healing	 and	 embryogenesis.	 However,	 the	 processes	 of	 senescence	
and	immune	clearance	are	dysregulated	during	aging,	where	senescent	
cells accumulate in tissues contributing to the onset and progression 
of multiple age-related disorders through a variety of cell autonomous 





Conclusive evidence is accumulating that therapy-induced se-
nescent	 cells	 (both	 with	 a	 cancerous	 and	 stromal	 origin)	 can	 drive	
tumorigenesis,	 either	 by	 releasing	 complex	 pro-inflammatory	 and	
tumour-promoting	 SASP	 cocktails	 (Faget,	 Ren,	 &	 Stewart,	 2019;	
Gonzalez-Meljem,	 Apps,	 Fraser,	 &	 Martinez-Barbera,	 2018),	 or	 by	
the	reversion	of	the	cell	cycle	arrest	and	the	acquisition	of	stemness	
and	 aggressive	 clonogenic	 growth	 potentials	 (Lee	 &	 Schmitt,	 2019).	
Genotoxic	stress,	which	is	induced	by	many	chemotherapies,	promotes	
cellular	senescence.	Remarkably,	it	has	been	shown	that	chemothera-
py-induced senescent breast cancer cells can promote tumour relapse 
in	the	lung	(Demaria	et	al.,	2017),	and	senescent	stromal	cells	form	the	
niche	that	promotes	metastasis	 in	the	bone	 (Luo	et	al.,	2016).	 In	the	
case	of	NSCLC,	neoadjuvant	platinum-based	chemotherapy	results	 in	
the accumulation of senescent cancer cells in patients and evidence 
has been found of the escape of replicative arrest in humans (thera-
py-induced)	senescent	 lung	cancer	cells	 (Roberson,	Kussick,	Vallieres,	
Chen,	 &	Wu,	 2005).	 Therefore,	 treatment	 modalities	 that	 eliminate	
therapy-induced senescent cells may be critical for tumour eradication.
Recent research has identified targetable vulnerabilities of senes-
cent	cells	that	can	be	exploited	by	a	novel	group	of	drugs	called	seno-





nations of tyrosine kinase inhibitors and flavonoids (e.g. dasatinib and 
quercetin;	 Zhu	 et	 al.,	 2015);	 FOXO4-p53	 interfering	 peptides	 (Baar	
et	al.,	2017);	HSP90	chaperone	inhibitors	(Fuhrmann-Stroissnigg	et	al.,	











models	 showing	 high	 potency	 in	 killing	 senescent	 cells—however,	 it	
also	has	significant	on-target	haematological	toxicity,	including	throm-
bocytopenia	(Cang,	Iragavarapu,	Savooji,	Song,	&	Liu,	2015).	This	nar-
rows its therapeutic window and can preclude concomitant treatment 
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with	other	agents	with	haematological	toxicities.	While	targetable	vul-
nerabilities	of	senescence	have	been	discovered,	these	are	often	also	
present in nonsenescent tissues leading to problems with specifically 
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that the encapsulation of nanoparticles with galacto-oligosaccharides 
(GalNPs)	is	an	efficient	method	to	preferentially	deliver	cytotoxic	drugs	
and	tracers	to	the	lysosomes	of	senescent	cells	where	SA-β-gal activ-




administration with the senescence-inducing anti-cancer treatment 
palbociclib	 effectively	 halts	 tumour	 growth	 in	 xenograft	 models	 of	
melanoma	and	non-small-cell	lung	cancer	(NSCLC)	(Muñoz-Espín	et	al.,	
2018).	We	have	also	shown	that	a	fluorescent	probe	covalently	linked	
to multi-acetylated galactose is preferentially digested by senescent 
cells,	 releasing	 the	 free	 fluorophore	 (Lozano-Torres	et	 al.,	2017).	The	
presence of multiple acetyl moieties in the galactose residue is thought 








the	 senescence-inducing	 chemotherapy	 cisplatin	 (CDDP)	 efficiently	
arrests tumour progression in models of orthotopically transplanted 
murine	lung	adenocarcinoma	cells,	and	in	a	tumour	xenograft	model	
of	human	NSCLC.	 Importantly,	galacto-conjugation	of	Navitoclax	re-
duces thrombocytopenia in treated mice at therapeutically effective 
doses,	as	well	as	apoptosis	of	platelets	in	human	blood	samples	treated	
ex	vivo.	Overall,	we	propose	galacto-conjugation	of	cytotoxic	drugs	as	
a versatile methodology for developing second-generation prodrugs 
with	high	senolytic	activity	and	reduced	toxicity.	We	provide	evidence	
of the efficacy of combining senescence-inducing chemotherapies 
with	senotherapies	in	cancer,	with	potential	for	clinical	application.
2  | RESULTS
2.1 | Synthesis, characterization and hydrolysis 
reaction studies
RNA	 interference	and	drug	 screening	approaches	 led	 to	 the	 iden-
tification	 of	 the	 anti-apoptotic	 BCL-2	 protein	 family	 as	 potential	
therapeutic	 targets	 in	 senescent	 cells,	 and	 Navitoclax	 (ABT-263)	
as	a	drug	with	a	potent	senolytic	activity	 (Chang	et	al.,	2016;	Zhu	
et	al.,	2016).	Here,	we	have	engineered	a	novel	prodrug,	namely	Nav-
Gal,	 by	modifying	 the	molecular	 structure	 of	Navitoclax	 following	
the	synthetic	procedure	shown	in	Figure	S1A.	To	do	so,	Navitoclax	
was	reacted	with	2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bro-
mide	 (Gal)	 through	 bimolecular	 nucleophilic	 substitution	 (SN2)	 in	
the presence of potassium carbonate yielding the Nav-Gal prodrug 
(Figure	 1b),	 which	 was	 comprehensively	 characterized	 by	 several	
nuclear	magnetic	resonance	techniques	(NMR),	 including	1H-NMR,	
13C-NMR	and	correlated	spectroscopy	 (COSY)	NMR,	as	well	as	by	
attenuated	 total	 reflectance	 (ATR)	 and	high-resolution	mass	 spec-
trometry	 (HRMS)	 (Figures	 S1B–F).	 The	 1H	NMR	 signal	 centred	 at	
5.6	 ppm	 (Figure	 S1B)	 corresponds	 to	 the	 anomeric	 proton	 of	 the	
attached galactose and indicates the successful covalent linkage of 
the	monosaccharide	 to	Navitoclax.	 In	 addition,	 the	 appearance	 of	
a	signal	centred	at	1,749	cm−1	in	the	ATR	spectra	(Figure	S1E)	indi-
cates that galactose remains acetylated after purification. Correct 
functionalization	to	the	nitrogen	atom	of	bis(sulfonyl)aniline	 is	 fur-
ther corroborated through the fragmentation peaks observed in the 
mass	spectrum	(Figure	S1F).	After	extensive	structural	characteriza-
tion,	we	examined	the	ability	of	Nav-Gal	to	be	enzymatically	hydro-
lyzed	 to	Navitoclax.	GLB1	 is	 the	human	 lysosomal	β-galactosidase 
responsible	 for	 the	 SA-β-gal	 activity	 (Dimri	 et	 al.,	 1995).	We	used	
high	 performance	 liquid	 chromatography	 (HPLC)	 to	 examine	 the	
time-dependent	 hydrolysis	 reaction	 of	 PBS	 (pH	 7)-DMSO	 (0.01%)	
solutions	containing	Nav-Gal	in	the	presence	of	recombinant	GLB1	
and	compared	the	peaks	with	those	of	Navitoclax	 (Figure	1c).	The	
obtained chromatograms showed the Nav-Gal peak with the sub-
sequent	appearance	of	free	Navitoclax	signal	in	the	presence	of	the	
β-galactosidase activity of the lysosomal enzyme and confirmed that 
Nav-Gal was completely hydrolyzed. No significant spontaneous 
Nav-Gal	hydrolysis	was	observed	(data	not	shown).
2.2 | Nav-Gal is a prodrug with effective 
wide-ranging senolytic activity that depends on 
GLB1 activity
Since	 senescent	 cells	 are	 commonly	 characterized	 by	 high	 lyso-
somal	SA-β-gal	activity,	we	hypothesized	that	galacto-conjugated	
Navitoclax	 would	 be	 preferentially	 processed	 and	 activated	 in	








senescent HCTT116 cells (n	=	3),	(h)	irradiation-induced	senescent	MLg	cells	(n	=	3)	and	(i)	oncogene-induced	senescent	IMR90	cells	
(previously	treated	for	72	hr	with	200	nM	4-hydroxytamoxifen	(4-OHT))	(n=3).	Data	in	(e-i)	represent	mean	±	SD	of	replicates,	and	statistical	
significance	was	calculated	using	two-way	ANOVA	;	*p	<	.05,	**p	<	.01,	***p < .001; #p	<	.05,	##p	<	.01,	###p < .001
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senescent cells and hence could function as a prodrug with more 
selective	senolytic	activity.	To	investigate	this,	we	performed	cell	
viability assays using a model of therapy-induced senescence. The 





Navitoclax	 required	 to	 induce	death	 in	50%	of	 the	 cells,	 termed	
half	maximal	inhibitory	concentration	(IC50),	after	72	hr	of	treat-
ment	was	1.926	µM	for	nonsenescent	and	0.122	µM	for	cisplatin-
induced	 senescent	 A549	 cells,	 while	 the	 IC50	 for	 Nav-Gal	 was	
9.758	 µM	 for	 nonsenescent	 and	 0.275	 µM	 for	 senescent	 A549	
cells	(Figure	2b).	A	similar	approach	was	performed	in	a	model	of	
palbociclib-induced senescence with a human melanoma cell line 
(SK-Mel-103)	(Figure	2c,d	and	Figure	S2A-C).	These	results	show	
(in	 two	 different	 models	 of	 chemotherapy-induced	 senescence)	
that	Nav-Gal	has	an	improved	senolytic	index	over	Navitoclax	and	
indicates that this effect is mainly mediated by a higher degree of 
protection	of	nonsenescent	cells	from	cytotoxic	activity.	In	an	at-
tempt to determine whether senolytic activity and nonsenescent 
cell	protection	by	Nav-Gal	were	more	widely	observed,	we	 then	
performed cell viability assays using a variety of cell lines and di-
verse	triggers	of	cellular	senescence.	Figure	2e-i	show	the	effects	
on	cell	viability	of	both	Navitoclax	and	Nav-Gal	at	different	con-
centrations in cisplatin-induced senescent mouse lung adenocar-
cinoma (KrasG12D/+;p53−/−	(KP)	L1475(luc)	cells)	(Turrell	et	al.,	2017),	
palbociclib-induced	senescent	mouse	breast	cancer	4T1	cells,	dox-
orubicin-induced senescent human colorectal carcinoma HCT116 
cells,	irradiation-induced	senescent	mouse	lung	fibroblasts	(MLg)	
and	oncogene-induced	senescent	human	lung	fibroblasts	(IMR90),	
versus their nonsenescent counterparts. Efficient implementation 
of	cellular	senescence	using	these	triggers	was	confirmed	by	SA-β-
gal	staining	and	Western	blotting	for	senescence	markers	(Figure	
S2A-C).	 In	 all	 the	human/murine	 cell	 types	 tested,	 and	 indepen-
dently	of	the	senescence-inducing	trigger	used,	Nav-Gal	showed	
effective senolytic activity and a significantly higher degree of 
protection	of	nonsenescent	cells	when	compared	to	Navitoclax.
To determine whether the senolytic effect of the prodrug Nav-
Gal depends on the increased lysosomal β-galactosidase activity 
of	 senescent	 cells,	 siRNAs	were	used	 to	 knock-down	 the	expres-
sion of GLB1	in	A549	and	SK-Mel-103	cells.	As	shown	in	Figure	3a-
f,	 siRNA2	 efficiently	 downregulated	 the	 transcription	 of	GLB1 at 









2.3 | Nav-Gal induces apoptosis of senescent cells 
while preserving viability of nonsenescent cells
The	 use	 of	 Navitoclax	 has	 been	 described	 to	 induce	 apoptosis	
preferentially	 in	 senescent	 cells	 through	 inhibition	 of	 the	 BCL-2-
regulated	 pathway	 (Zhu	 et	 al.,	 2016).	 To	 assess	 whether	 Nav-Gal	
and	Navitoclax	killed	senescent	cells	by	the	same	end	mechanism,	
cisplatin-induced	senescent	lung	cancer	A549	cells	and	palbociclib-
induced	 senescent	melanoma	 SK-Mel-103	 cells	were	 treated	with	
Navitoclax	or	Nav-Gal	 (or	vehicle)	 in	parallel,	with	automated	real-
time measurement of apoptosis study using a live-cell analysis sys-
tem.	Figure	4a,b	and	Figure	S3A–D	show	that	treatment	with	either	
Navitoclax	 or	Nav-Gal	 induced	 apoptosis	 preferentially	 in	 chemo-










sults indicate that Nav-Gal kills senescent cells by inducing apopto-
sis and that it protects against nonsenescent cell death to a higher 
extent	than	Navitoclax.
F I G U R E  3   GLB1	transient	downregulation	prevents	the	senolytic	activity	of	Nav-Gal.	(a)	Representative	images	of	SA-β-gal staining of 
control	and	cisplatin-induced	senescent	A549	cells	48	hr	after	transfection	with	scrambled	siRNA,	siRNA	1	and	siRNA	2.	Scale	bar	=	200	μm. 
(b)	Percentage	of	SA-β-gal-positive	cells	in	conditions	presented	in	(a).	Bars	represent	mean	±	SD (n	=	3).	(c)	GLB1 fold change gene 
expression	in	control	and	senescent	A549	cells	48	hr	post-transfection	with	different	siRNAs.	(d)	Representative	images	of	SA-β-gal staining 
of	control	and	palbociclib-induced	senescent	SK-Mel-103	cells	48	hr	after	transfection	with	scrambled	siRNA,	siRNA	1	and	siRNA	2.	Scale	
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2.4 | Cisplatin and Nav-Gal have additive anti-
tumour effects when used concurrently and 
sequentially
Effective anti-cancer treatments have enhanced clinically ben-
eficial	 effects	 when	 given	 in	 combination,	 including	 in	 NSCLC.	
We	 therefore	 next	 sought	 to	 ascertain	 the	 efficacy	 of	 concur-
rent	 cisplatin	 and	Nav-Gal	 treatment	 in	 vitro.	We	 first	 used	 clo-
nogenic assays to determine the efficacy of the combination of 
senescence-inducing	 cisplatin	 and	 Navitoclax,	 Nav-Gal	 or	 vehi-
cle,	 administered	 concomitantly	 to	 A549	 cells.	 Compared	 with	
monotherapies,	the	combination	of	cisplatin	and	a	senolytic	drug	
was substantially more effective at inhibiting cell proliferation 
(Figure	 4c-f).	 From	 0	 to	 2	 µM	 cisplatin,	 as	 the	 concentration	 of	
both	Navitoclax	and	Nav-Gal	 increases,	additional	 impairment	of	






mal β-galactosidase	 activity.	While	both	 senolytic	drugs	 showed	
an	additive	effect	 in	combination	with	cisplatin,	 increasing	doses	
of	Nav-Gal	 exhibited	 coefficients	 of	 drug	 interactions	 (CDIs)	 <1	
and closer to 0 in combination with 1 μM	 cisplatin	 (Figure	 4g),	
which suggests that the combination of drugs may be synergistic 
(Zhao	et	al.,	2014).	Of	note,	these	observations	were	also	validated	
in	the	context	of	a	sequential	treatment,	where	colonies	were	first	
exposed	to	 increasing	concentrations	of	cisplatin	 for	7	days,	 fol-
lowed	by	7	days	of	senotherapy	(Figure	S3E,F).
2.5 | Therapeutic activity of Nav-Gal in 
xenografts and orthotopic models of NSCLC
In order to validate the efficiency of the prodrug Nav-Gal in com-
bination	with	senescence-inducing	chemotherapy	in	vivo,	we	used	
a	 model	 whereby	 A549	 cells	 were	 transplanted	 subcutaneously	
into	the	flanks	of	severe	combined	immunodeficient	(SCID)	mice.	
In	 a	 first	 approach,	 we	 aimed	 to	 assess	 the	 induction	 of	 senes-
cence in tumour-bearing mice treated with cisplatin. Histological 
analyses of the tumours collected after treatment showed evi-
dence of senescence induction upon cisplatin administration (as 
inferred	from	SA-β-gal	positivity)	(Figure	5a).	The	effects	of	con-
comitant treatment with cisplatin and each senolytic were then in-
vestigated. Once tumours reached an average volume of 100 mm3,	
mice	 were	 treated	 with	 cisplatin	 and	 daily	 doses	 of	 Navitoclax	










logical analyses of the tumours revealed that cisplatin treatment 
results	 in	 increased	p21	positivity	 (correlating	with	Western	blot	
analyses	 of	 cisplatin-treated	 cells	 in	 vitro,	 Figure	 S2C)	 and	 de-
creased	 Ki67	 positivity,	which	 together	 constitute	 a	 hallmark	 of	
senescent	cells	 (Figure	5d,e).	Treatment	with	cisplatin	and	either	
Navitoclax	or	Nav-Gal	 exhibited	 reduced	 levels	of	 p21	and	Ki67	
positivity,	 alongside	 a	 strong	 TUNEL	 signal,	 strongly	 suggesting	
that apoptosis of senescent cells facilitates the anti-tumour effect. 
Additionally,	a	therapeutic	effect	of	both	Navitoclax	and	Nav-Gal	
in	 tumour	 growth	was	 observed	 in	 a	 sequential	 treatment	 after	
one	week	 of	 cisplatin	 administration,	 suggesting	 a	 potential	 ap-
plication	as	adjuvant	 therapy	 for	clearing	senescent	cells	 (Figure	
S4A,B).
To obtain further evidence of the therapeutic potential of 
Nav-Gal in combination with senescence-inducing chemotherapy 
in	a	more	physiological	context,	we	used	an	orthotopic	model	of	
NSCLC.	 Here,	 wild-type	 C57BL/6J	 mice	 were	 transplanted	 (via	
tail	vein	injection)	with	a	syngeneic	luciferase-expressing	KP	lung	
adenocarcinoma	 cell	 line	 (L1475luc)	 (Turrell	 et	 al.,	 2017).	 Once	
tumours	were	established	in	the	lungs,	baseline	luciferase	signals	
were obtained and mice were then treated for 10 days with cispla-
tin	alone,	cisplatin	and	Nav-Gal	 in	combination,	or	 their	vehicles	
in	 combination,	 using	 the	 experimental	 scheme	 shown	 in	 Figure	
S5A.	Representative	images	of	the	luciferase	signal	at	initial-	and	
end-points	are	shown	in	Figure	S5B.	Luciferase	signal	monitoring	
F I G U R E  4   The galacto-conjugated prodrug Nav-Gal shows an enhanced effect when combined to senescence-inducing cisplatin 
treatment	and	a	lower	induction	of	apoptosis	of	nonsenescent	cells.	(a)	Representative	images	of	cell	viability	showing	staining	for	annexin	
V	(red)	of	control	or	cisplatin-induced	senescent	A549	cells,	exposed	to	vehicle,	Navitoclax	(10	μM)	or	Nav-Gal	(10	μM)	treatment	over	







to untreated condition (n	=	3).	(g)	Co-coefficient	of	drug	interaction	(CDI)	value	trend	of	Navitoclax	and	Nav-Gal	across	0.5	μM	cisplatin	
treatment	(left)	and	1	μM	cisplatin	treatment	(right).	CDI	<	1	(yellow	area)	indicates	a	synergistic	effect,	where	CDI	values	closer	to	0	
correlate	to	higher	synergy	between	the	drugs	concomitantly	used.	Data	represent	mean	±	SD (n	=	3)
10 of 19  |     GONZÁLEZ-GUALDA Et AL.
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demonstrated that concomitant treatment of the mice with cis-
platin	and	Nav-Gal	significantly	decreased	tumour	burden	(Figure	
S5C)	 compared	with	cisplatin	monotherapy.	Histological	 analysis	
of the lungs showed high burden of senescent cells only in cis-
platin-treated	mice	 (as	evidenced	by	 increased	SA-β-gal and p21 
levels),	and	decreased	SA-β-gal	and	p21	levels	and	higher	TUNEL	
staining	in	mice	concomitantly	treated	with	cisplatin	and	Nav-Gal,	
indicating enhanced apoptosis of senescent cells (representative 
areas	are	shown	in	Figure	S5D).
Taken	 together,	 these	 results	 demonstrate	 that	 the	 combina-
tion of senescence-inducing therapy with senotherapy is highly 
effective	 in	 inhibiting	 tumour	 growth	 in	 vivo,	 providing	preclinical	
proof-of-principle of the therapeutic benefits of using Nav-Gal as a 
potent prodrug with senolytic activity.
2.6 | Nav-Gal has reduced platelet toxicity when 
compared with Navitoclax
Thrombocytopenia	 is	 a	major	 dose-limiting,	 and	 clinically	 impor-
tant,	 toxicity	 that	 is	 produced	 by	 Navitoclax	 in	 human	 patients	
(Cang	 et	 al.,	 2015;	Wilson	 et	 al.,	 2010).	 A	 potential	 benefit	 for	
galacto-conjugation of senolytic drugs is the reduction of their as-
sociated	toxicities,	and	the	potential	widening	of	their	therapeu-
tic windows. To determine whether galacto-conjugation affected 
platelet	 toxicity,	 we	 performed	 ex	 vivo	 experiments	 with	 both	
human	and	murine	blood	 samples	where	we	exposed	 the	whole	
blood	 to	 increasing	 concentrations	 of	 either	 Navitoclax	 or	 Nav-
Gal,	 using	 fluorescein-labelled	 annexin	 V	 to	 identify	 apoptotic	
platelets	by	 flow	cytometry	 ((Vogler	et	al.,	2011);	Figure	S6A,B).	
As	observed	in	Figure	6a,b	for	human	blood	and	in	Figure	6c,d	for	
mouse	blood,	when	 samples	were	exposed	 to	 the	 same	concen-
trations	 of	 Navitoclax	 and	 Nav-Gal,	 the	 proportion	 of	 platelets	
with	 annexin	V	 signal	was	 significantly	 higher	 after	 exposure	 to	
Navitoclax	than	with	Nav-Gal.	This	effect	persists	in	both	models,	
despite	a	significant	difference	in	platelet	sensitivity	to	BCL-2	fam-
ily inhibition between each model.
To determine whether Nav-Gal also protected platelet levels 
at	 therapeutic	 doses	 in	 vivo,	we	 first	 examined	 the	platelet	 count	
of	 wild-type	 C57BL/6J	 treated	 daily	 with	 senotherapy	 for	 a	 total	
of	 10	 days	 (Figure	 6e).	 As	 shown	 in	 Figure	 6f,	 daily	 administra-
tion	of	Navitoclax	 resulted	 in	 severe	 thrombocytopenia	 after	only	
5	days	of	treatment,	 independently	of	the	route	of	administration.	
Remarkably,	 Nav-Gal	 treatment	 did	 not	 cause	 thrombocytopenia	






nificant additional thrombocytopenia was observed in the group 
treated	with	 cisplatin	 and	Nav-Gal	 (cf.	Navitoclax).	We	also	 found	











In	 the	 last	decade,	 the	use	of	novel	genetically	engineered	mouse	
models has demonstrated that the selective elimination of senescent 
cells attenuates a number of age-related pathologies and promotes 
the	healthspan	and	lifespan	of	mice	(Baker	et	al.,	2016).	These	ob-
servations resulted in the development of senotherapies—therapies 
aimed	at	interfering	with	cellular	senescence,	either	by	killing	senes-
cent	cells	(senolytics)	or	by	inhibiting	the	SASP	(senomorphics	or	se-




report a versatile methodology for the generation of prodrugs that 
permits	a	more	selective	senolytic	activity.	We	show	that	galacto-
conjugation	 of	 the	BCL-2	 family	 inhibitor	Navitoclax	 allows	 thera-
peutically	relevant	activity	in	subcutaneous	tumour	xenografts	and	
orthotopic mouse models of chemotherapy-induced senescence 
in	the	context	of	lung	carcinoma.	In	addition,	this	strategy	reduces	
Navitoclax-associated	thrombocytopenia	in	treated	mice,	and	plate-
let apoptosis in human and murine blood samples.
Targeting cellular senescence by galacto-conjugation relies on the 
high levels of lysosomal β-galactosidase	(SA-β-gal)	activity	present	in	
multiple	types	of	senescent	cells.	Although	SA-β-gal is an imperfect 
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marker	 of	 senescence,	 diseased	 tissues	 are	 often	 positive	 for	 this	
marker,	particularly	when	senescent	cells	accumulate	and	persist	in	
damaged	areas	 (Hernandez-Segura	et	al.,	2018;	Sharpless	&	Sherr,	
2015).	 To	 exploit	 the	 accumulated	 pathological	 SA-β-gal	 activity,	
we previously used beads with a mesoporous silica core that were 
functionally capped with a homogeneous coating of galacto-oligo-
saccharides,	thereby	allowing	the	encapsulation	of	cytotoxic	drugs,	
including	doxorubicin	and	Navitoclax,	as	well	as	fluorescent	tracers	
for the detection of senescent cells. This nanotechnology-enabled 
preferential	cargo	release	within	senescent	cells,	and	the	efficacy	of	
this approach was validated in models of bleomycin-induced pulmo-
nary	fibrosis	and	palbociclib-treated	melanoma	and	NSCLC	tumours	
(Muñoz-Espín	et	al.,	2018).	However,	despite	the	emergent	interest	
in the development of nanomedicine and the considerable technical 
success of an increasing number of nanotechnologies in preclinical 
models,	only	a	 small	number	of	 formulations	have	 reached	clinical	
translation. The current limitations stem from an incomplete under-
standing	of	nano-bio	interactions,	potential	toxicities,	and	challenges	
regarding	biodistribution,	such	as	systemic	trafficking,	presence	of	
physiological	 barriers,	 mechanisms	 of	 cellular	 uptake,	 pharmaco-









sidase	 activity-driven,	 cleavable	 acetylated	 galactose	 results	 in	 an	
effective prodrug that enhances its selective senolytic activity (over 
the	parent	drug)	in	a	variety	of	cell	types	and	senescence	triggered	
by	different	stimuli,	suggesting	a	potentially	universal	approach	for	
senescent cell targeting. This includes cisplatin-induced senescence 
in	human	(A549)	and	mouse	(KP)	lung	cancer	lines;	human	melanoma	
(SK-Mel-103)	and	mouse	mammary	gland	(4T1)	cancer	cell	lines	re-
sponsive	 to	 palbociclib;	 doxorubicin-induced	 senescent	 colorectal	
carcinoma	 cells	 (HCT116);	mouse	 lung	 fibroblasts	 (MLg	 cells)	 sub-
jected	to	X-ray	radiation	and	human	lung	fibroblasts	undergoing	on-
cogene-induced	senescence	(ER:Mek	IMR90	cells).	Since	Navitoclax	
is	 a	 potent	 small-molecule	 inhibitor	 of	 BCL-2,	 BCL-XL,	 and	 BCL-W 




cells	 in	 two	models	of	 chemotherapy-induced	senescence,	namely	
cisplatin-induced	 senescent	 A549	 lung	 cancer	 cells	 and	 palboci-
clib-induced	senescent	SK-Mel-103	melanoma	cells,	thereby	indicat-





simultaneous administration of Nav-Gal with the standard-of-care 
senescence-inducing cisplatin (widely used in the management of 
NSCLC	patients)	 resulted	 in	 reduced	 tumour	burden	 in	SCID	mice	
bearing	subcutaneous	tumour	xenografts	comprised	of	human	A549	
lung cancer cells. Concomitant treatment with cisplatin and Nav-Gal 
also reduced tumour burden in an orthotopic transplantation model 
using	 murine	 KP	 lung	 adenocarcinoma	 cells.	 Nav-Gal	 administra-
tion showed a strong effect in reducing tumour growth during both 
sequential	 and	concomitant	 treatment	with	 cisplatin.	Combination	
treatment suggests an additive/synergistic effect between cispla-
tin	and	Nav-Gal,	as	observed	 in	our	clonogenic	assays	and	further	
confirmed	by	the	calculated	coefficient	of	drug	interaction	(CDI).	It	
is	 important	 to	 note	 that	 neither	Navitoclax	 nor	Nav-Gal	 had	 any	
relevant impact on tumour burden in the absence of cisplatin in our 
murine	models,	strongly	suggesting	a	therapeutic	activity	restricted	
to the induction of senescence or whenever tumours contain senes-
cent	areas,	but	not	in	fully	proliferative	tumours.	These	observations	


















mean	±	SEM.	Two-way	ANOVA	followed	by	Bonferroni	post-tests	or	one-tailed	t tests was performed to calculate the significance of the 
results;	*	p	<	.05;	***p	<	.001;	****p < .0001
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reinforce	the	concept	of	Nav-Gal	as	a	senolytic	prodrug	and,	more	
generally,	open	up	 the	possibility	of	using	 senotherapies	as	prom-
ising adjuncts to treat cancer in combination with senescence-in-
ducing chemotherapies. The eradication of senescent cancer cells 
by Nav-Gal may also prevent tumour progression by mitigating the 
senescent	secretome	(SASP)	and	its	broad	range	of	potential	protu-
morigenic	effects	(Faget	et	al.,	2019).	In	this	regard,	cancer	therapies	
can induce senescence not only in cancer cells but also in stromal 
cells,	and	this	 is	also	the	case	 in	 lung	cancer	patients	subjected	to	
platinum-	 and	 taxane-based	 chemotherapy	 regimens	 (Roberson	
et	al.,	2005).	Stromal	senescence	appears	to	establish	an	 immuno-




data reinforce the concept that combination treatments comprised 
of senescence-inducing radio/chemotherapy and senolytics might 




including	 thrombocytopenia	 (Cang	et	 al.,	 2015),	 presenting	partic-
ular	 challenges	when	 given	 in	 combination	with	 cytotoxic	 chemo-
therapies	 which	 also	 have	 dose-limiting	 haematological	 toxicities.	
For	Navitoclax,	this	occurs	because	of	the	importance	of	BCL-XL in 
platelet	survival,	and	the	gradual	reduction	of	its	levels	by	Navitoclax	
promotes a change in the molecular clock that determines platelet 
lifespan	leading	to	the	pro-apoptotic	activity	of	BAK	(Mason	et	al.,	
2007).	 In	 addition	 to	 thrombocytopenia,	 the	 first	 trial	 to	 evaluate	
Navitoclax	in	 lymphoid	malignancies	resulted	in	grade	III	transami-
nitis and gastrointestinal bleed in a proportion of patients subjected 
to	a	continuous	dosing	schedule	 (Wilson	et	al.,	2010).	The	modifi-
cation	of	Navitoclax	with	an	acetylated	galactose	may	prevent	the	
exposure	of	 healthy	 (nonsenescent)	 cells	 to	 the	 inhibitory	 activity	
of	 BCL-2	 family	 protein	 members	 and,	 thereby,	 reduce	 unwanted	
side	effects.	In	support	of	this,	our	IC50	experiments	with	A549	cells	






Nav-Gal is similar and results in the complete eradication of these 
cells,	nonsenescent	cancer	cells	were	substantially	more	protected	
from	the	induction	of	apoptosis	when	exposed	to	Nav-Gal,	indicat-










expression)	 while	 maintaining	 anti-cancer	 properties.	 In	 addition,	
DT2216	specifically	targets	BCL-XL,	but	not	BCL-2	or	BCL-W,	which	






lacto-conjugated	Navitoclax	 (Nav-Gal)	 selectively	 kills	 a	 variety	 of	
human and murine cell types undergoing senescence by different 
stressors in vitro and that it has therapeutic efficacy in combination 
with	cisplatin	in	murine	NSCLC	models.	Importantly,	we	also	demon-
strate that galacto-conjugation of senolytics can reduce potential 
toxicities	of	the	conjugated	drug.	The	development	of	galacto-conju-
gated prodrugs has considerable promise for improving cancer treat-
ment,	as	well	as	other	human	senescence-related	disorders.
4  | E XPERIMENTAL PROCEDURES
4.1 | Synthesis of Nav-Gal prodrug
For	 the	 synthesis	 of	 Nav-Gal	 prodrug,	 40	 mg	 (0.04	 mmol)	 of	
Navitoclax	 (Eurodiagnostico),	 25	mg	 (0.06	mmol)	 of	 2,3,4,6-tetra-
O-acetyl-α-D-galactopyranosyl-bromide	 (Sigma)	 and	 10.5	 mg	
(0.07	mmol)	of	K2CO3	 (Sigma)	were	mixed.	Anhydrous	acetonitrile	
(Sigma)	was	added,	and	the	mixture	was	stirred	at	70°C	for	3	hr	under	
argon-enriched atmosphere. The solvent was eliminated under vac-






on a single flash chromatography column as described above.
4.2 | Characterisation of Nav-Gal prodrug
Nav-Gal	 was	 characterized	 by	 conventional	 techniques.	 For	 sam-









formed	 in	 a	Bruker	 Tensor	 27	 FT-IR	 (Ettlingen,	Germany)	 at	 room	
temperature	and	analyzed	with	OPUS	Data	Collection	Program	 (V	
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1.1).	 Finally,	 high	 resolution	 mass	 spectrometry	 (HRMS)	 was	 re-
corded	with	an	ABSciex	TRIPLETOF	T5600.
4.3 | Hydrolysis reaction of Nav-Gal studies
For	 hydrolysis	 reaction	 studies,	 aqueous	 solutions	 of	Navitoclax	
and Nav-Gal at a concentration of 10–5	M	(pH	7)	in	0.01%	DMSO	
were prepared. Human β-galactosidase	(Biotechne,	R&D	Systems)	
was then added to Nav-Gal solutions to a final concentration of 
8	ng/µl,	and	chromatograms	were	acquired	after	complete	reaction	
(λexc	=	365	nm)	with	a	Waters	1525	binary	HPLC	pump	equipped	
with	 a	Waters	 2990	 diode	 array	 detector.	 Chromatograms	were	






The	 human	 lung	 carcinoma	 cell	 line	 A549	was	 obtained	 from	 the	
European	 Collection	 of	 Authenticated	 Cell	 Cultures	 (ECACC).	 SK-
MEL-103	 (human	melanoma),	4T1	 (breast	cancer),	HCT116	 (human	
colorectal	 carcinoma)	 and	MLg	 (mouse	 lung	 fibroblastic)	 cell	 lines	
were	obtained	from	the	American	Type	Culture	Collection	(ATCC).	
The	murine	 KP	 lung	 adenocarcinoma	 cell	 line	 L1475	 was	 derived	
from KrasLSL-G12D/+;p53Fx/Fx	 mice	 (Jackson	 et	 al.,	 2005)	 and	
transduced	with	MSCV-luciferase-hygromycin	 retrovirus,	 as	 previ-




cells	 were	 cultured	 in	 DMEM-F-12	 culture	 media	 (Sigma)	 supple-
mented	with	2	mM	l-Glutamine	and	10%	FBS.	ER:Mek	IMR90	cells	
were	cultured	in	phenol	red-free	DMEM	(Sigma)	supplemented	with	
10%	FBS,	 2	mM	 l-Glutamine	 and	 1	mM	 sodium	pyruvate	 (Sigma).	
All	cells	were	incubated	in	20%	O2	and	5%	CO2	at	37°C.	Cells	were	
routinely	 tested	 for	 mycoplasma	 using	 the	 universal	 Mycoplasma	
Detection	Kit		(ATCC)	or	by	RNA-capture	ELISA.
For	senescence	induction,	A549	cells	were	treated	with	15	µM	








in	 sterile	 PBS;	 palbociclib	 (Eurodiagnostico),	 Navitoclax	 (Stratech)	
and	Nav-Gal	were	reconstituted	in	DMSO.	For	in	vivo	experiments,	













Gene	 expression	 of	 GLB1	 and	 ACTB	 genes	 was	 measured	 by	
quantitative	real-time	PCR	performed	on	a	QuantStudio	thermocy-
cler	 (Applied	Biosystems)	 following	 Luna®	Universal	 qPCR	Master	
Mix	 (New	England	Biolabs)	protocol	and	amplification	parameters,	
and	using	predesigned	KiCqStart®	SYBR®	Green	Primers	H_GLB1_1	
and	 H_ACTB_1	 pairs	 (Sigma-Aldrich).	 Relative	 quantification	 was	
carried	out	using	2−ΔΔCt methodology.
4.6 | Cell viability and apoptosis analysis
For	A549,	SK-MEL-103,	4T1,	HCT116	and	ER:Mek	IMR90	cell	lines,	
control and senescent cells were seeded in flat-bottom-clear 96-
well	plates	at	a	density	of	6,000–8,000	and	4,000–6,000	cells	per	
well,	 respectively.	The	 following	day	cells	were	 treated	with	 serial	
dilutions	 of	Nav-Gal	 or	Navitoclax	 in	 0.2%	 FBS-containing	media.	
Viability	was	assessed	48	or	72	hr	later	after	two	hours	of	incuba-
tion	 at	 37°C	with	 CellTiter-Glo®	 Luminescent	 Cell	 Viability	 Assay	
(Promega)	 or	 CellTiter-Blue®	 Cell	 Viability	 Reagent	 (Promega).	








72	 hr,	 viability	 was	 assessed	 with	 CellTiter-Blue® Cell Viability 
Reagent	(Promega)	as	described	above.
To determine the induction of apoptosis after the treatment with 
Navitoclax	and	Nav-Gal,	4,000	senescent	and	6,000	nonsenescent	
A549	or	SK-Mel-103	cells	were	seeded	in	96-well	plates.	24	hr	later,	
annexin	 V	 Fluorescent	 Reagent	 (Essen	 Bioscience)	 was	 added	 to	
the	media,	and	after	a	first	scan,	the	cells	were	treated	with	vehicle	
(DMSO),	11	µM	Navitoclax	or	11	µM	Nav-Gal	for	48	hr.	Images	were	
collected every 2 hr with an Incucyte®	S3	Live-Cell	Analysis	System	
microscope	 (Essen	Bioscience)	over	 time.	A	 total	of	2	pictures	per	
well	were	analyzed	using	the	IncuCyte	ZOOM™	software	analyser,	
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per well in a 6-well plate and allowed to attach overnight. In a 
first	 approach	 (concomitant	 treatment),	 cells	 were	 then	 treated	
with increasing and concomitant concentrations of cisplatin and 
Navitoclax	 or	 Nav-Gal.	 In	 a	 second	 approach	 (sequential	 treat-




PFA	 for	 10	 min.	 They	 were	 then	 permeabilized	 using	 ice-cold	
methanol	for	20	min,	and	left	to	dry.	Colonies	were	then	stained	
with	0.5%	crystal	violet	 for	30	min,	and	excess	was	 removed	by	
thoroughly washing three times with deionised water. Colonies 




Multimode	 Spectrophotometer	 (PECAN)	 microplate	 reader.	 The	
blank	 (10%	 acetic	 acid)	was	 subtracted	 from	 each	OD	measure-
ment,	and	the	average	value	for	each	experimental	condition	was	
calculated and normalized against clonogenic potential value ob-
tained in no-treatment condition.
To analyze the synergistic effect of the concomitant treatment 
of	 cisplatin	 and	 the	 senolytics	Navitoclax	 and	Nav-Gal,	 we	 calcu-
lated	the	co-coefficient	of	drug	interaction	(CDI)	using	the	normal-
ized clonogenic potential values of the individual and concomitant 
treatments at different concentrations. CDIs were calculated as 
ratios	following	the	formula	CDI	=	(AB)/(AxB),	where	AB	is	the	clo-
nogenic potential value of the concomitant treatment with the two 
drugs	combined	at	a	specific	concentration,	and	A	and	B	are	the	clo-
nogenic potential values of the individual treatments of each drug 
at	 such	concentration.	Following	 this	 formula,	 a	CDI	>	1	 indicates	
that	the	drugs	are	antagonistic,	a	CDI	=	1	 indicates	that	the	drugs	
are	additive	and	a	CDI	<	1	indicates	that	the	drugs	are	synergistic,	





Cell	 lysis	was	 performed	 using	 RIPA	 buffer	 (Sigma)	 supplemented	
with	 phosphatase	 inhibitors	 (PhosSTOP™	 EASYpak	 Phosphatase	
Inhibitors	 Cocktail,	 Roche)	 and	 protease	 inhibitors	 (cOmplete™	
Protease	 Inhibitor	 Cocktail,	 Roche).	 Proteins	 were	 quantified	 and	
separated	by	SDS-PAGE	and	transferred	to	polyvinylidene	difluoride	
(PVDF)	 membranes	 (Millipore)	 according	 to	 standard	 protocols.	
Membranes	were	 immunoblotted	with	antibodies	against	p21	and	




at	 room	 temperature	 and	 subsequently	 incubated	 with	 Enhanced	




All	 mice	 were	 treated	 in	 strict	 accordance	 with	 the	 local	 ethical	
committee	 (University	 of	 Cambridge	 Licence	 Review	 Committee)	
and	the	UK	Home	Office	guidelines.	For	the	orthotopic	model	ex-
periment,	5–6	weeks	old	C57BL/6J	mice	were	 transplanted	 in	 the	
lungs with 3 × 105	 syngeneic	 luciferase-expressing	KP	 (L1475(luc))	
lung	 tumour	 cells	 via	 tail-vein	 injection.	 All	mice	were	maintained	
in ventilated cages within a specific pathogen free animal facility. 
Luminescence	values	were	recorded	5	days	later	after	i.p.	injection	
with	D-luciferin	(150	mg/kg	body	weight,	PerkinElmer)	using	an	IVIS	













the formula length × width2/2.	 When	 tumour	 volume	 reached	 an	
average of 100 mm3,	mice	were	 randomized	 and	 assigned	 to	 one	
of the control or therapy groups. Therapy was initiated with either 
vehicle,	 1.5	 mg/kg	 cisplatin	 (CDDP,	 via	 intraperitoneal	 (i.p.)	 injec-
tion)	three	times	per	week,	100	mg/kg	Navitoclax	(via	oral	gavage)	
5	days	ON/2	days	OFF,	85	mg/kg	Nav-Gal	(via	i.p.	injection)	5	days	
ON/2	 days	 OFF,	 or	 a	 combination	 of	 the	 mentioned	 drugs.	 Mice	
were culled by cervical dislocation after 3 weeks of treatment.
For	 platelet	 toxicity	 analysis,	 wild-type	 C57BL/6J	 mice	 were	
treated	daily	with	100	mg/kg	Navitoclax	(via	oral	gavage),	85	mg/kg	
Navitoclax	(via	i.p.	injection)	or	85	mg/kg	Nav-Gal	(via	i.p.	injection)	
for 10 consecutive days.
To	 analyze	 platelet	 count	 in	 mice,	 blood	 was	 collected	 by	
cardiac	 puncture	 during	 isoflurane	 anaesthesia	 in	 xenograft	 ex-
perimental	mice,	 and	by	 superficial	 vessel	 puncture	 in	wild-type	
C57BL/6J	 experimental	 mice.	 Blood	 was	 collected	 into	 antico-
agulating	Microvette®	 tubes	 (Sarstedt),	 and	 platelet	 levels	 were	
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immediately	measured	 using	 a	 Scil	 Vet	 abc	 Plus	 hematology	 an-
alyzer	(Horiba).
4.10 | Histology
SA-β-Gal staining was performed in frozen tissue sections using 
the	 Senescence	β-Galactosidase	 Staining	 kit	 (Cell	 Signaling),	 fol-






affin	 sections	 were	 deparaffinized	 and	 re-hydrated,	 and	 slides	
were	incubated	with	anti-p21	(Abcam)	and	Ki67	(Abcam)	antibod-
ies	 at	4°C	overnight,	 or	processed	 for	TUNEL	 staining	using	 the	
DeadEnd™	 fluorometric	 TUNEL	 System	 (Promega)	 as	 per	manu-
facturer's	 instructions.	 Immunohistological	 reaction	was	 of	 p21,	
and	 Ki67	 was	 developed	 using	 3,3-diaminobenzidine	 tetrahy-
drochloride	 (DAB),	 and	 nuclei	 counterstained	 with	 haematoxy-
lin.	 For	 immunofluorescence,	 frozen	 tissue	 sections	 were	 either	
processed	 for	TUNEL	 staining	using	 the	 above	mentioned	 kit	 or	
alternatively	fixed	in	4%	PFA	for	10	min,	permeabilized	with	0.5%	
Triton™	X-100	 for	 3	min	 and	 subsequently	 blocked	with	Normal	
Donkey	 Serum	 for	 1	 hr	 at	 room	 temperature.	 They	 were	 then	
probed	with	anti-p21	(Abcam)	and	Ki67	(Abcam)	antibodies	at	4°C	
overnight.	The	following	day,	sections	were	incubated	with	Anti-
Rat	 IgG	555	and	Anti-Rabbit	 IgG	488	secondary	antibodies	 (Cell	
Signaling	Technologies),	briefly	incubated	in	DAPI-containing	PBS,	
and	mounted	 using	 Fluoromount-G™	Mounting	Medium.	 Images	





unteers	 was	 extracted	 according	 the	 UPV	 ethics	 procedures	 and	
processed	 essentially	 as	 shown	 in	Vogler	 et	 al.,	 2011).	 For	mouse	
platelet	apoptosis	assay,	blood	from	five	wild-type	C57BL/6J	mice	
was collected by cardiac puncture in accordance with the University 







with	 Annexin	 Binding	 Buffer	 (Thermo	 Fisher	 Scientific)	 and	 incu-
bated	for	10	min	with	Annexin	V-FITC	(Immunostep)	and	CD-41-PE	





for	 human	 samples	 and	 an	 LSR	Fortessa	 cell	 analyzer	 running	 the	
FACSDiva	 software	 (BD	 Biosciences)	 for	 mouse	 samples.	 FlowJo	




one-	 and	 two-way	ANOVA,	 Student's	 t	 tests	 and	Bonferroni	 post	
hoc	tests	using	Prism	5	software	(GraphPad)	as	indicated.	A	p-value 
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